RTW Biotech Opportunities (LON:RTW – Get Free Report) traded down 0.5% during trading on Thursday . The stock traded as low as GBX 1.99 and last traded at GBX 1.99. 74,251 shares were traded during trading, a decline of 84% from the average session volume of 466,356 shares. The stock had previously closed at GBX 2.
RTW Biotech Opportunities Price Performance
The business has a fifty day moving average of GBX 2.15 and a two-hundred day moving average of GBX 1.86. The company has a debt-to-equity ratio of 22.51, a quick ratio of 0.81 and a current ratio of 1.26. The firm has a market capitalization of £6.49 million, a price-to-earnings ratio of -0.08 and a beta of 0.60.
RTW Biotech Opportunities Company Profile
RTW Biotech Opportunities Ltd (LSE: RTW) is an investment fund focused on identifying transformative assets with high growth potential across the biopharmaceutical and medical technology sectors. Driven by a long-term approach to support innovative businesses, RTW Bio invests in companies developing next-generation therapies and technologies that can significantly improve patients’ lives. RTW Bio is managed by RTW Investments, LP, a leading healthcare-focused entrepreneurial investment firm with deep scientific expertise and a strong track record of supporting companies developing life-changing therapies.
Featured Articles
- Five stocks we like better than RTW Biotech Opportunities
- Silver Is the New Oil—And the World’s Running Dry
- BNZI stands out as a Zacks Buy. Earnings momentum and analyst upgrades align
- What happened in Cyprus could be coming here
- Elon Musk’s $1 Quadrillion AI IPO
- Buffett, Gates and Bezos Quietly Dumping Stocks—Here’s Why
Receive News & Ratings for RTW Biotech Opportunities Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RTW Biotech Opportunities and related companies with MarketBeat.com's FREE daily email newsletter.
